Sanofi now faces an investor class action over its weight-loss drug Zimulti. And it may have Amgen investors to thank. A few weeks after the U.S. Supreme Court cleared Amgen shareholders to ask for class-action status, U.S. District Judge George Daniels said Sanofi's investors could band together for their legal fight.
Amgen touted top-line results from a Phase III trial of an anti-cancer virus as a treatment for a deadly form of skin cancer, showing that talimogene laherparepvec met the primary goal for shrinking tumors in patients with late stages of the disease.
Roger Perlmutter is back. About a year after the Amgen R&D chief was squeezed out in a top-level reshuffling at the big biotech, Merck says they have tapped him to run the Big Pharma's research house, which has been consuming $8 billion a year without a lot to show for it.
Amgen was accused last month of getting special favors from lawmakers. Today the U.S. Supreme Court ruled against it in a securities case that sets precedent for the industry and beyond.
The FDA has halted a study in children of the Amgen ($AMGN) drug Sensipar after a 14-year-old died during the trial. While the FDA says it does not know yet if the drug was the cause of the death, it halted the trial as a precaution. Sensipar stirred up ire last month when it was learned that the drug received special price protections in the fiscal cliff bill.
While DTC advertising spending has backed off from the $5-billion-a-year highs set during the boom years of the last decade, significant sums are still spent, particularly by the top 10 spenders. Here are the numbers >>
Drugmakers Affymax and Takeda are investigating whether manufacturing is playing a role in the allergic reactions that have resulted in three deaths and led it to recall all of its anemia drug Omontys from the market.
When it comes to drug delivery, it's hard these days to overlook the buzzing field of nanoengineering. Highly targeted nanoparticles are on the cutting edge of the growing field, and according to BIND Biosciences' Jeff Hrkach, there are big things in store for the tiny drug carriers.
As Amgen pursues a new strategy of picking pipeline winners, the biotech giant and partner UCB have scuttled plans for late-stage development of their experimental antibody to speed up healing of bone fractures.
Under the provocative headline "Game Poacher or Gamekeeper – Big Pharma's Stance on Biosimilars", Forbes contributor Simon King delineates the multi-pronged strategy of Amgen in the biosimilars game.